摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-methylphenyl)-N-[3-(morpholin-4-yl)propyl]-9H-beta-carboline-3-carboxamide

中文名称
——
中文别名
——
英文名称
1-(4-methylphenyl)-N-[3-(morpholin-4-yl)propyl]-9H-beta-carboline-3-carboxamide
英文别名
1-(4-methylphenyl)-N-(3-morpholin-4-ylpropyl)-9H-pyrido[3,4-b]indole-3-carboxamide
1-(4-methylphenyl)-N-[3-(morpholin-4-yl)propyl]-9H-beta-carboline-3-carboxamide化学式
CAS
——
化学式
C26H28N4O2
mdl
——
分子量
428.5
InChiKey
AOAIVWHJDSQHEK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    70.2
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • Inhibitors of RAD52 recombination protein and methods using same
    申请人:Mazin Alexander V.
    公开号:US10442817B2
    公开(公告)日:2019-10-15
    The present invention includes novel RAD52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
    本发明包括新型 RAD52 抑制剂,用于预防或治疗有需要的受试者的癌症。本发明还包括一种预防或治疗有需要的受试者癌症的方法,该方法包括向受试者施用有效量的本发明化合物。在某些实施方案中,受试者进一步施用至少一种额外的治疗剂。
  • Inhibitors of RAD52 Recombination Protein and Methods Using Same
    申请人:MAZIN Alexander V.
    公开号:US20180134727A1
    公开(公告)日:2018-05-17
    The present invention includes novel RAD52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
查看更多